WVE-007 Obesity Drug Explained: Clinical Trial Results and Potential
The obesity drug market has been transformed by GLP-1 medicines, but the next major opportunity may come from treatments that work in an entirely different way. One experimental drug attracting growing attention is WVE-007 , an obesity candidate being developed by Wave Life Sciences (NASDAQ: WVE) . Instead of targeting appetite through the GLP-1 pathway, WVE-007 is designed to silence INHBE , a gene associated with body-fat distribution and metabolic health. Early clinical results have been especially interesting because WVE-007 has shown reductions in total and visceral fat while preserving lean mass after a single dose. The drug may also eventually offer much less frequent dosing than today's weekly obesity injections. WVE-007 at a Glance Developer: Wave Life Sciences Drug type: GalNAc-siRNA Target: INHBE / Activin E Lead indication: Obesity Clinical program: INLIGHT Current development: Phase 2a multidose testing underway Potential advantage: Fat reducti...